

**DATA SHEET**  
**Hsa-miR-517a fluoresceinated oligo probe****Catalog No.**  
**HM517a-100****Description**  
One vial of 0.650 ml of probe in hybridization buffer**Analyte Specific Reagent. Analytical and performance characteristics are not established.**

Doc. No. 932-HM517a-100

Rev. B

Date of release: 18-Aug-2020

**Description**

The Hsa-miR-517 probe has been designed from mature human miR-517 sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

**Specifications**

The Hsa-miR-374 identifies mature miR-374 sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

**Storage and Handling**

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

**Precautions:**

For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

**Quality Control**

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

**References**

1. Chen X, Hao B, Han G, Liu Y, Dai D, Li Y et al. (2014) miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2. *J. Cell. Biochem.* 116, 225–232.
2. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y et al. (2010) CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. *Nucleic Acids Res.* 38, 5366–5383.
3. Huang X, Huang M, Kong L, Li Y. (2015) miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. *Cell Prolif.* 2015 Oct;48(5):593-9.
4. Li G, Zhang Z, Tu Y, Jin T, Liang H, Cui G, He S, Gao G. (2013) Correlation of microRNA-372 upregulation with poor prognosis in human glioma. *Diagn Pathol.* 2013 Jan 8;8:1.
5. Wu G, Wang Y, Lu X, He H, Liu H, Meng X, Xia S, Zheng K, Liu B. (2015) Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. *BMC Cancer.* 2015 Mar 26;15:182

**BioGenex Quality Control Testing Conditions**

<b>Parameter</b>	<b>Conditions used</b>
Control Tissue	Normal Thyroid(FB-HM517A-3p).
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues